Market Newsdesk

Equity Insider

News Commentary

Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC
, Aug. 14, 2025 /PRNewswire/ — Equity InsiderNews Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it appears that the private sector continues to step up, with hundreds of millions of VC dollars pouring into oncology ventures so far in 2025. While there has been a recent victory in the Senate to restore $15 million for the Pancreatic Cancer Research Program (PCARP), the prior elimination of the only federal program dedicated solely to researching pancreatic cancer served as a stark reminder of these ongoing funding challenges. This dynamic is setting the stage for a “flight to quality” among investors, who are now more than ever looking for innovative leaders with strong pipelines and clear paths to regulatory execution, a key milestone that can separate a promising biotech from a potential breakthrough like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), ProPhase Labs, Inc. (NASDAQ: PRPH), IO Biotech, Inc. (NASDAQ: IOBT), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), and PDS Biotechnology Corporation (NASDAQ: PDSB).

According to a report from Global Market Insights, the global oncology market was estimated at US$345.1 billion in 2025, and while growing at an impressive 10.8% CAGR, is projected to reach US$866.1 billion by 2034 — with $377.1 billion of that coming from the USA alone. Even more optimistic is a report from Vision Research Reports, which sees the global cancer drug sector surpassing US$900 billion in sales by 2034.

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for its flagship asset, pelareorep.

In its latest Q2 2025 report, the company confirmed it has begun formal discussions with the U.S. Food and Drug Administration (FDA) aimed at finalizing a pivotal study design, with trial start-up activities expected to begin as early as Q4 2025.

For investors and potential partners, this represents a clear transition from promising clinical data to potential regulatory approval in one of medicine’s most challenging cancer types.

“We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year,” said Jared Kelly, CEO of Oncolytics. “As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors.”

The strategic focus on mPDAC reflects both compelling clinical results and a significant market opportunity. Pelareorep is a systemically delivered oncolytic virus designed to convert immunologically “cold” tumors—those typically invisible to the immune system—into “hot” tumors that can respond to immunotherapy. In first-line pancreatic cancer studies, pelareorep-based regimens have demonstrated a notable 21.9% two-year overall survival rate, compared to a 9.2% historical benchmark for standard chemotherapy alone.

Even more compelling, when pelareorep was combined with chemotherapy and a checkpoint inhibitor, researchers recorded a 62% objective response rate—particularly significant given that checkpoint inhibitors are not currently approved for use in this indication. These results stem from pelareorep’s dual mechanism: it both replicates within cancer cells and activates the body’s immune response against tumors.

“This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep’s immune-mediated mechanism of action,” said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. “We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME—all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep.”

Translational data from the GOBLET and AWARE-1 studies demonstrate how pelareorep transforms the tumor microenvironment, increasing PD-L1 expression, heightening interferon signaling, and mobilizing tumor-infiltrating lymphocytes in the blood—changes that correlate with tumor size reduction. This mechanistic validation, combined with survival data from over 1,100 patients across multiple studies, has solidified the company’s decision to prioritize this indication.

Oncolytics’ execution-focused strategy is being led by Jared Kelly and Andrew Aromando, who both played key roles in Ambrx Biopharma’s US$2 billion acquisition by Johnson & Johnson. Kelly was appointed CEO earlier this year, while Aromando recently joined as Chief Business Officer. In line with their focus on capital efficiency, the company has terminated its At-the-Market and Equity Line of Credit facilities, citing sufficient resources to advance key milestones without near-term shareholder dilution.

Regulatory advantages are already in place to accelerate development. Pelareorep holds Fast Track and Orphan Drug designations for pancreatic cancer from the FDA, meaning the agency has already recognized both the drug’s potential and the serious unmet need in this patient population. These statuses streamline review processes and enhance the program’s attractiveness to potential pharmaceutical partners.

The context underscores the opportunity: pancreatic cancer remains one of the deadliest common cancers, with a five-year survival rate of less than 14%. Unlike other cancers where immunotherapies have transformed treatment, mPDAC has largely resisted immunotherapeutic approaches—making pelareorep’s immune-activating mechanism particularly promising for this underserved patient population.

Back in July, Oncolytics hosted a key opinion leader event featuring gastrointestinal cancer experts who reviewed survival outcomes for patients and biomarker validation. The expert panel reinforced the view that pelareorep’s mechanism of activating innate and adaptive immune responses is both biologically sound and commercially relevant for first-line mPDAC treatment.

With this latest milestone, Oncolytics is entering a phase where FDA feedback will shape both clinical plans and potential commercial partnerships. If the agency accepts the company’s proposed trial framework centered on an overall survival endpoint, the resulting study could provide definitive proof of pelareorep’s market potential in mPDAC.

The company expects to provide an updated clinical timeline in Q3 2025, with trial start-up activities potentially beginning as early as Q4 2025. With compelling survival data, regulatory designations in place, and an experienced leadership team driving execution, Oncolytics is positioning pelareorep for a pivotal test in one of oncology’s most challenging and underserved markets.

CONTINUED… Read this and more news for Oncolytics Biotech at:
  https://equity-insider.com/2025/03/18/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ 

In other recent industry developments and happenings in the market include:

ProPhase Labs, Inc. (NASDAQ: PRPH) announced it received a U.S. patent for its BE-Smart test that can detect early signs of Barrett’s esophageal cancer, a deadly disease that kills most patients because it’s usually caught too late. The test works with simple brush and forceps biopsies and achieved over 95% accuracy in clinical testing, potentially allowing doctors to catch this cancer when it’s still treatable.

“This achievement, coming on the heels of our BE-Smart^™ validation demonstrating greater than a 95% technical success rate and dual compatibility with both brush and forceps biopsies, solidifies our leadership in medical innovation and brings us one step closer to transforming early detection and treatment strategies for this serious condition,” said Ted Karkus, CEP of ProPhase. “With this newly issued patent, we believe we are well positioned to accelerate commercialization and broaden clinical access to BE-Smart.”

ProPhase’s breakthrough could save thousands of lives by identifying patients at high risk for esophageal cancer before the disease becomes incurable, representing a major advancement in early cancer detection.

IO Biotech, Inc. (NASDAQ: IOBT) recently announced that its experimental cancer vaccine (Cylembio) meaningfully extended the time before advanced melanoma patients got worse, with patients living 19.4 months without disease progression compared to 11 months for those on standard treatment alone. The vaccine works by training the immune system to attack both cancer cells and the cells that help tumors hide from treatment, and it showed particularly strong results in patients whose tumors were PD-L1 negative and unlikely to respond to current immunotherapies.

“In this study, we observed a highly encouraging improvement in progression free survival and consistent trend in overall survival in patients treated with Cylembio,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. “The magnitude and durability of clinical effect observed consistently across subgroups supports our confidence in Cylembio and its potential as a treatment for advanced melanoma patients. We look forward to engaging with the FDA to determine a potential path to approval based on these data.”

IO Biotech plans to meet with the FDA this fall to discuss approval for this treatment that could become a new standard of care for the deadliest form of skin cancer.

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) reported progress on its experimental breast cancer pill called palazestrant, which is designed to completely block estrogen signals that fuel most breast cancers and is currently being tested in two large Phase 3 trials expected to finish in 2026.

“Having achieved regulatory alignment on the selected dose for our pivotal palazestrant program during the second quarter, we are focused on accelerating enrollment in OPERA-01, which is on track for top-line data in the second half of 2026,” said Sean P. Bohen, M.D., Ph.D., President and CEO of Olema. “Palazestrant’s demonstrated activity and combinability with multiple compounds offers the potential for it to become a best-in-class, backbone endocrine therapy for metastatic breast cancer.”

The company is also developing OP-3136, a pill that targets a different pathway cancer cells use to grow and spread, with early results expected in 2026. Olema’s drugs are designed to work where current treatments fail, potentially offering hope to the thousands of breast cancer patients whose tumors eventually become resistant to existing therapies.

PDS Biotechnology Corporation (NASDAQ: PDSB) reported promising results from a colorectal cancer study where its experimental treatment achieved impressive response rates, leading to expansion of the trial to treat more patients with this hard-to-treat cancer.

“Our second quarter of 2025 and recent weeks have been a productive period for PDS Biotech, highlighted by the continued progress in our VERSATILE-003 Phase 3 clinical trial,” said Frank Bedu-Addo, Ph.D., President and CEO of PDS Biotech. “We look forward to publishing the full data set for this trial later this year, as we continue to progress our VERSATILE-003 trial, the only registrational stage trial specifically targeting HPV16-positive HNSCC patients.”

The company’s lead program targets head and neck cancers caused by HPV, the same virus that is a major cause of cervical cancer, and is currently being tested in the only late-stage trial specifically designed for these patients. PDS Biotech’s approach uses its immune-boosting technology to help the body’s natural defenses better recognize and destroy cancer cells, potentially offering new hope for patients with limited treatment options.

Source:
https://equity-insider.com/2025/03/18/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ 

CONTACT:

Equity Insider


[email protected]


(604) 265-2873

DISCLAIMER:
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Logo – https://mma.prnewswire.com/media/2644233/5460937/Equity_Insider_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/biotech-stocks-rally-as-oncology-market-targets-866b-by-2034-302530410.html

SOURCE Equity Insider

USA News Group

News Commentary

Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC
, Aug. 14, 2025 /PRNewswire/ — USA News GroupNews Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate’s recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), Fate Therapeutics, Inc. (NASDAQ: FATE), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and Nektar Therapeutics (NASDAQ: NKTR).

Global Market Insights estimates the global oncology market at US$345.1 billion in 2025 and forecasts it will climb to US$866.1 billion by 2034, growing at a robust 10.8% CAGR. The U.S. alone is expected to contribute $377.1 billion to that total. Vision Research Reports projects an even larger figure for the global cancer drug sector, predicting it will surpass US$900 billion in sales by 2034.

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for its flagship asset, pelareorep.

In its latest Q2 2025 report, the company confirmed it has begun formal discussions with the U.S. Food and Drug Administration (FDA) aimed at finalizing a pivotal study design, with trial start-up activities expected to begin as early as Q4 2025.

For investors and potential partners, this represents a clear transition from promising clinical data to potential regulatory approval in one of medicine’s most challenging cancer types.

“We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year,” said Jared Kelly, CEO of Oncolytics. “As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors.”

The strategic focus on mPDAC reflects both compelling clinical results and a significant market opportunity. Pelareorep is a systemically delivered oncolytic virus designed to convert immunologically “cold” tumors—those typically invisible to the immune system—into “hot” tumors that can respond to immunotherapy. In first-line pancreatic cancer studies, pelareorep-based regimens have demonstrated a notable 21.9% two-year overall survival rate, compared to a 9.2% historical benchmark for standard chemotherapy alone.

Even more compelling, when pelareorep was combined with chemotherapy and a checkpoint inhibitor, researchers recorded a 62% objective response rate—particularly significant given that checkpoint inhibitors are not currently approved for use in this indication. These results stem from pelareorep’s dual mechanism: it both replicates within cancer cells and activates the body’s immune response against tumors.

“This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep’s immune-mediated mechanism of action,” said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. “We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME—all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep.”

Translational data from the GOBLET and AWARE-1 studies demonstrate how pelareorep transforms the tumor microenvironment, increasing PD-L1 expression, heightening interferon signaling, and mobilizing tumor-infiltrating lymphocytes in the blood—changes that correlate with tumor size reduction. This mechanistic validation, combined with survival data from over 1,100 patients across multiple studies, has solidified the company’s decision to prioritize this indication.

Oncolytics’ execution-focused strategy is being led by Jared Kelly and Andrew Aromando, who both played key roles in Ambrx Biopharma’s US$2 billion acquisition by Johnson & Johnson. Kelly was appointed CEO earlier this year, while Aromando recently joined as Chief Business Officer. In line with their focus on capital efficiency, the company has terminated its At-the-Market and Equity Line of Credit facilities, citing sufficient resources to advance key milestones without near-term shareholder dilution.

Regulatory advantages are already in place to accelerate development. Pelareorep holds Fast Track and Orphan Drug designations for pancreatic cancer from the FDA, meaning the agency has already recognized both the drug’s potential and the serious unmet need in this patient population. These statuses streamline review processes and enhance the program’s attractiveness to potential pharmaceutical partners.

The context underscores the opportunity: pancreatic cancer remains one of the deadliest common cancers, with a five-year survival rate of less than 14%. Unlike other cancers where immunotherapies have transformed treatment, mPDAC has largely resisted immunotherapeutic approaches—making pelareorep’s immune-activating mechanism particularly promising for this underserved patient population.

Back in July, Oncolytics hosted a key opinion leader event featuring gastrointestinal cancer experts who reviewed survival outcomes for patients and biomarker validation. The expert panel reinforced the view that pelareorep’s mechanism of activating innate and adaptive immune responses is both biologically sound and commercially relevant for first-line mPDAC treatment.

With this latest milestone, Oncolytics is entering a phase where FDA feedback will shape both clinical plans and potential commercial partnerships. If the agency accepts the company’s proposed trial framework centered on an overall survival endpoint, the resulting study could provide definitive proof of pelareorep’s market potential in mPDAC.

The company expects to provide an updated clinical timeline in Q3 2025, with trial start-up activities potentially beginning as early as Q4 2025. With compelling survival data, regulatory designations in place, and an experienced leadership team driving execution, Oncolytics is positioning pelareorep for a pivotal test in one of oncology’s most challenging and underserved markets.

CONTINUED… Read this and more news for Oncolytics Biotech at:
  https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ 

In other recent industry developments and happenings in the market include:

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported strong Q2 2025 results with $60 million in total product revenue, driven primarily by its breakthrough melanoma therapy Amtagvi, which treated over 100 patients in the second quarter.

“Growth for Amtagvi and Proleukin will continue in the second half of 2025 as existing ATC growth continues and large community practices begin treating patients,” said Frederick Vogt, Ph.D., J.D., Interim President and CEO of Iovance. “We expect our first ex-U.S. regulatory approval imminently and remain on track to provide updates on our clinical programs.”

The company’s tumor-infiltrating lymphocyte (TIL) therapy—which uses a patient’s own immune cells to fight cancer—generated $54.1 million in revenue and represents the first FDA-approved T-cell therapy for solid tumors, offering new hope for advanced melanoma patients who have tried other treatments without success.

With expanded clinical trials planned for lung cancer and endometrial cancer, plus international approvals expected in Canada and other markets, Iovance is positioned to bring its innovative cancer treatment to patients worldwide.

Fate Therapeutics, Inc. (NASDAQ: FATE) recently announced promising clinical progress for its off-the-shelf CAR T-cell therapy FT819, which showed lasting responses in lupus patients and received FDA clearance to begin trials for a solid tumor program targeting MICA/B proteins. While primarily focused on autoimmune diseases, the company’s next-generation FT836 CAR T-cell therapy represents a significant advancement in cancer treatment as it’s designed to target solid tumors without requiring harsh conditioning chemotherapy, potentially making the treatment safer and more accessible.

“Building on this momentum, we are also working closely with the FDA under our RMAT designation with the goal of commencing our registrational study for FT819 in SLE and LN in 2026,” said Bob Valamehr, Ph.D., MBA, President and CEO of Fate Therapeutics.

“Additionally, we continue to strengthen our broader pipeline programs with an extended partnership with Ono Pharmaceuticals, and advancements in bringing our next-generation, off-the-shelf CAR T cells with Sword and Shield™ technology toward the clinic.”

The company’s stem cell-based platform continues to advance multiple programs, including partnerships for HER2-positive solid tumors, positioning Fate as a leader in developing ready-made cancer cell therapies.

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) remains on track to submit its application for INO-3107 in the second half of 2025, targeting Recurrent Respiratory Papillomatosis (RRP), a rare cancer-related condition caused by HPV that affects the airways. The company’s DNA medicine platform represents a novel approach to treating HPV-related diseases and cancers, with INO-3107 showing significant clinical benefit by reducing the need for repeated surgeries in RRP patients from an average of 4.1 procedures annually to just 0.9 procedures.

“We believe that INO-3107 could become the preferred treatment option for Recurrent Respiratory Papillomatosis (RRP) patients and their physicians—a treatment option with the potential to change the trajectory of this disease,” said Dr. Jacqueline Shea, President and CEO of INOVIO. “I look forward to building on the significant progress of this past quarter and providing updates as we work toward a potential approval date in mid-2026.”

Beyond RRP, Inovio’s technology platform is designed to treat various HPV-related cancers and other tumors by teaching the body’s immune system to recognize and fight cancer cells. With breakthrough therapy designation from the FDA and plans for a trial involving 100 patients, INO-3107 could become the first DNA-based therapy approved for treating this serious cancer-related condition.

Nektar Therapeutics (NASDAQ: NKTR) reported impressive Phase 2b data for rezpegaldesleukin in treating moderate to severe atopic dermatitis, with the company positioning this immune system regulator as a first-in-class treatment for autoimmune diseases. While primarily focused on autoimmune conditions, Nektar’spipeline includes NKTR-255, a treatment designed to boost the immune system’s ability to fight cancer, which is being tested in multiple ongoing clinical trials with various partners.

“As a first-in-class, T regulatory cell biologic, rezpegaldesleukin is poised to become an important novel mechanism to treat millions of patients with autoimmune disorders,” said Howard W. Robin, President and CEO of Nektar. “Finally, we are making significant progress on advancing preclinical studies with a new bispecific antibody, NKTR-0166, which combines the TNFR2 epitope with a validated antibody target.”

The company’s technology platform creates novel treatments that could potentially address both autoimmune diseases and cancer by enhancing the immune system’s cancer-fighting abilities. With additional data expected from hair loss trials in December 2025 and continued development of next-generation programs, Nektar is advancing a unique approach to immune system therapy that could benefit millions of patients with serious diseases.

Source:
https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ 

CONTACT:

USA NEWS GROUP 


[email protected]


(604) 265-2873

DISCLAIMER:
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. 
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Logo – https://mma.prnewswire.com/media/2603685/5460912/USA_News_Group_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cancer-treatment-stocks-surge-as-866b-market-attracts-private-investment-302530406.html

SOURCE USA News Group

Equity Insider

News Commentary

Issued on behalf of CEA Industries, Inc.

VANCOUVER, BC
, Aug. 14, 2025 /PRNewswire/ — Equity InsiderNews Commentary – The corporate crypto revolution has moved from experiment to mainstream strategy, as public companies poured $47.3 billion into digital assets in 2025 alone, significantly outpacing ETF inflows of $31.7 billion and signaling a fundamental shift in how businesses manage their treasuries. This institutional embrace has been accelerated by regulatory clarity, with pro-crypto policies and the passage of legislation like the CLARITY Act creating a pathway for traditional corporations to treat digital assets as legitimate reserve holdings. Leading research firm DWF Ventures published comprehensive analysis showing that 14 major public companies now collectively hold $76 billion in digital assets, with $40 billion deployed in just the past year alone. The momentum shows no signs of slowing, as over 60 public companies have now confirmed cryptocurrency positions on their balance sheets, spanning everything from tech giants to entertainment companies, and pointing the market towards innovative crypto-focused companies including CEA Industries, Inc. (NASDAQ: BNC), BIT Mining Limited (NYSE: BTCM), Upexi, Inc. (NASDAQ: UPXI), Bitcoin Depot Inc. (NASDAQ: BTM), and Canaan Inc. (NASDAQ: CAN).

Mordor Intelligence forecasts the global cryptocurrency market will surge from $2.96 trillion in 2025 to $7.98 trillion by 2030, representing a robust 30.1% CAGR driven by institutional adoption and regulatory frameworks. Meanwhile, Grand View Research projects the cryptocurrency infrastructure market will expand from $5.70 billion in 2024 to $11.71 billion by 2030 at a 13.1% CAGR, reflecting the growing demand for institutional-grade crypto treasury solutions that these pioneering companies are racing to capture.

CEA Industries, Inc. (NASDAQ: BNC) isn’t your typical cryptocurrency story. While other companies scrambled to catch the Bitcoin wave or jumped on the latest trend, this Colorado-based firm made a calculated bet that could reshape how institutional investors think about digital assets.

In August 2025, CEA Industriescompleted a massive $500 million private placement specifically earmarked for one purpose: building the world’s largest corporate treasury of BNB tokens. The company immediately signaled its commitment by changing its ticker symbol from VAPE to BNC, reflecting its new identity as the premier publicly traded gateway to the BNB ecosystem.

But what exactly is BNB? Think of it as the fuel that powers one of the world’s busiest blockchain networks. BNB (originally called Binance Coin) is the native cryptocurrency of the BNB Chain ecosystem, which processes millions of transactions daily for everything from trading and payments to smart contracts and decentralized applications.

Unlike Bitcoin, which primarily serves as digital gold, BNB has real-world utility baked into its design. Users can stake it to earn rewards, pay transaction fees at discounted rates, and participate in the growing decentralized finance (DeFi) ecosystem. Perhaps most importantly, BNB features a quarterly “auto-burn” mechanism that permanently removes tokens from circulation, creating built-in scarcity that could benefit long-term holders.

Here’s where CEA Industries gets interesting. The company didn’t just raise money and hope for the best. They assembled what might be the most impressive crypto-focused management team on Wall Street.

David Namdar, co-founder of Galaxy Digital (one of the largest crypto investment firms), stepped in as CEO. Russell Read, former Chief Investment Officer at CalPERS (managing over $400 billion in assets) and Deputy CIO of Deutsche Bank Asset Management, joined as CIO. The board welcomed Hans Thomas, founding partner of 10X Capital, the firm managing BNC’s treasury strategy.

This isn’t a group of crypto newcomers making speculative bets. These are seasoned financial professionals who’ve managed billions of dollars and understand institutional-grade risk management.

The results speak for themselves. In August 2025, BNCannounced the purchase of 200,000 BNB tokens worth approximately $160 million, officially making it the largest corporate holder of BNB globally. This wasn’t just a headline grab—it demonstrated the company’s ability to execute on its strategy quickly and at scale.

The timing appears strategic. While BNB consistently ranks among the top five cryptocurrencies by market capitalization, most U.S. investors still can’t buy it directly through traditional brokerage accounts. CEA Industries recognized this gap and positioned itself as the solution, offering regulated, SEC-compliant access to BNB exposure without the complexity of crypto wallets or exchange accounts.

The company’s financial backing adds credibility to its mission. The $500 million raise attracted over 140 institutional and crypto-native investors, including Pantera Capital, Arche Capital, ExodusPoint Capital Management, and Blockchain.com. Cantor Fitzgerald & Co. served as lead financial advisor, bringing Wall Street expertise to the strategy.

What sets BNC apart from other crypto treasury companies is its singular focus. While competitors diversify across multiple digital assets, CEA Industries made an all-in bet on BNB Chain’s ecosystem growth. The company believes this focused approach will allow it to capture maximum value as institutional adoption accelerates.

The potential upside follows historical patterns. When MicroStrategy adopted Bitcoin as its primary treasury asset in 2020, the stock gained nearly 2,000% at its peak. Similar treasury strategies by companies like Janover (Solana) and MetaPlanet (Bitcoin) produced dramatic stock price moves following their announcements.

CEA Industries has positioned itself to potentially benefit from this same dynamic, but with an asset that powers one of the most active blockchain ecosystems on Earth. With plans to deploy the remaining treasury capital and potential access to an additional $750 million through warrant exercises, BNC appears built for the long game in an ecosystem that’s just getting started.

CONTINUED… Read this and more news for CEA Industries at:
  https://equity-insider.com/2025/08/13/beat-wall-street-to-the-trade-that-500-million-just-backed/

BIT Mining Limited (NYSE: BTCM) announced its strategic expansion into the Solana ecosystem on July 10, 2025, marking a significant shift from traditional Bitcoin mining to building a robust SOL treasury worth up to $300 million.

“While we continue to make progress in our crypto mining operations, we have strategically shifted our focus to actively explore opportunities within the Solana ecosystem,” remarked Mr. Xianfeng Yang, CEO of BIT Mining. “This move reflects our commitment to capturing broader market potential and aligning with emerging trends that can drive long-term value and growth for the Company.”

The cryptocurrency mining company plans to raise between $200-300 million in phases to convert existing crypto holdings into SOL tokens while also operating validator nodes to support network decentralization and earn staking rewards. This strategic transformation positions BIT Mining to capture emerging opportunities in the rapidly growing Solana blockchain ecosystem, leveraging its existing infrastructure and technical expertise to create sustainable shareholder value.

Upexi, Inc. (NASDAQ: UPXI) announced it surpassed 2 million SOL tokens in its treasury as of August 4, 2025, representing a massive 172% increase from 735,692 SOL at the end of June following a $200 million capital raise.

“July was a game-changing month for Upexi, particularly with respect to accretive capital raises and a resulting drastic increase in our Solana treasury,” said Allan Marshall, CEO of Upexi. “During the month, we raised over $200 million and grew our Solana holdings by over 172% to 2 million SOL. And we continued to generate additional value for shareholders via an estimated 8% staking yield and additional purchases of discounted locked Solana.”

The brand owner turned crypto treasury company now holds approximately $334 million worth of Solana tokens, with substantially all coins being staked to earn roughly 8% annual yield, generating about $65,000 per day in revenue. Upexi has positioned itself as a pure-play Solana investment vehicle for public market investors, trading at attractive valuations relative to its underlying SOL holdings while benefiting from built-in gains through purchasing locked SOL at discounted prices.

Bitcoin Depot Inc. (NASDAQ: BTM) reported strong Q2 2025 financial results on August 12, 2025, with revenue growing 6% year-over-year to $172.1 million and net income surging 183% to $12.3 million driven by expanded kiosk deployment and higher transaction volumes. The leading Bitcoin ATM operator, which operates over 8,800 kiosk locations across 47 states, significantly improved profitability with Adjusted EBITDA jumping 46% to $18.5 million while strengthening its balance sheet to nearly $60 million in cash and digital assets.

“With nearly $60 million in cash and digital assets, we are well-positioned to capitalize on growth opportunities, both in the U.S. and internationally,” said Brandon Mintz, Founder and CEO of Bitcoin Depot. “Looking ahead, we remain focused on scaling efficiently and delivering sustained value for our customers and shareholders.”

Bitcoin Depot also strategically added to its Bitcoin treasury holdings, bringing total Bitcoin reserves to 100.35 BTC, while simplifying its corporate structure and providing guidance for continued high-single-digit revenue growth in Q3 2025.

Canaan Inc. (NASDAQ: CAN) reported July 2025 production results showing the Bitcoin mining company mined 89 bitcoins during the month while increasing its total Bitcoin holdings to 1,511 BTC as part of its newly adopted cryptocurrency holding policy.

“We’re pleased to report quarter-over-quarter improvement in our bitcoin mining performance, with monthly production resulting in 89 bitcoins, driven by a stronger bitcoin price and lower average power costs,” said Nangeng Zhang, Chairman and CEO of Canaan. “In line with our recently announced Cryptocurrency Holding Policy, we retain bitcoins acquired through our daily operations as a long-term reserve asset. This policy allows us to accumulate bitcoin, and our total holdings at month-end were 1,511 bitcoins.”

The mining hardware manufacturer and operator faced some operational challenges with deployed hashrate declining to 7.95 EH/s and operating hashrate at 6.24 EH/s, primarily due to planned exits from underperforming hosting sites in favor of better-performing partners. Canaan continues to strengthen its position in the mining industry with recent major orders from public mining companies like Cipher Mining and CleanSpark, while maintaining operations across multiple regions including America, Kazakhstan, and other international locations.

Article Sources:

https://equity-insider.com/2025/08/13/beat-wall-street-to-the-trade-that-500-million-just-backed/ 

CONTACT:

Equity Insider

[email protected]

(604) 265-2873

DISCLAIMER:
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by Equity Insider on behalf of Market IQ Media Group Inc. (“MIQ”). MIQ has been paid a fee for CEA Industries Inc. advertising and digital media from Creative Digital Media Group (“CDMG”). There may be 3rd parties who may have shares of CEA Industries Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY does not own any shares of CEA Industries Inc. but reserve the right to buy and sell, and will buy and sell shares of CEA Industries Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved on behalf of CEA Industries Inc. by CDMG; this is a paid advertisement, we currently own shares of CEA Industries Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Logo – https://mma.prnewswire.com/media/2644233/5460920/Equity_Insider_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/crypto-treasury-revolution-how-47b-corporate-shift-creates-new-investment-opportunities-302530405.html

SOURCE Equity Insider

SAN ANTONIO
, Aug. 14, 2025 /PRNewswire/ — Corporate law firm Elder Bray & Bankler PC recently advised FGI Group, Inc. on its sale of Dynamic Systems to Quanta Services, Inc. (NYSE: PWR) for an upfront purchase price of $1.35 billion, and a potential earnout of up to $216 million. The upfront purchase price was paid in a mix of cash and publicly-traded stock of Quanta.

Founded in 1988 and headquartered in Austin, Texas, Dynamic Systems, one of the largest mechanical solutions providers in the country, is a premier, turnkey mechanical, plumbing and process infrastructure solutions provider with a diversified customer base and exposure to the attractive and growing technology, semiconductor, healthcare and other load center markets. Quanta is a leading provider of comprehensive infrastructure solutions for the electric and gas utility, renewable energy, technology, communications, pipeline and energy industries in the United States, Canada, Australia and select other international markets.

Elder Bray & Bankler provided comprehensive legal counsel to FGI Group throughout the transaction, including deal structuring, negotiation, and regulatory guidance.  The Elder Bray team was led by Scott Bankler and Jake McCloy, with key support from Matt Augustyn, Jake Pylman, Chip Sugg, and Austin Baker Wiese.

Elder Bray & Bankler is a Texas-based corporate law firm focused on complex business transactions, mergers and acquisitions and private equity. With decades of experience, the firm combines deep legal knowledge with a practical, business-minded approach to help clients achieve successful outcomes.

For more information regarding the transaction, please see Quanta’s press release.

For more information, please contact:
Laura Boulanger
[email protected]
P: 210 424 4520

View original content:https://www.prnewswire.com/news-releases/elder-bray–bankler-advises-on-sale-of-dynamic-systems-to-quanta-services-302530396.html

SOURCE Elder Bray & Bankler

LOS ANGELES
, Aug. 14, 2025 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with losses related to RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) have opportunity to lead the securities fraud class action lawsuit.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN RXSIGHT, INC. (RXST), CLICK HERE BEFORE SEPTEMBER 22, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

 What Is The Lawsuit About?
The complaint filed alleges that, between November 7, 2024 and July 8, 2025, Defendants failed to disclose to investors that: (1) the Company was experiencing “adoption challenges” and/or structural issues resulting in declines in sales and utilization; (2) Defendants had overstated the demand for RxSight’s products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz, 
Email us at: [email protected]
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rxsight-inc-rxst-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302529773.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

Mercury’s New Umbrella Insurance Better Protects


Floridians’ Personal Wealth Against Bodily Injury Claims

LOS ANGELES
, Aug. 14, 2025 /PRNewswire/ — Multi-vehicle crashes, dog bites or a delivery person being injured on your property are some of the unexpected events that are putting Floridians’ personal financial health at risk. In fact, bodily injury payouts continue to climb year over year since the pandemic started, with the average amount for a liability claim increasing by 35%, according to Mercury Insurance (NYSE: MCY). 

The recent trend of rising liability injury claims for home and auto owners that exceed traditional policy limits has moved Mercury to unveil an all-new personal umbrella insurance policy for Floridians that offers extra protection with bolstered coverages beginning at just over $1 a day.

Per Forbes Magazine, an umbrella insurance policy can be an excellent addition to your insurance portfolio if you need liability coverage that goes beyond what your base car insurance or home insurance policies provide. Umbrella insurance is a good way to cover your net worth if you were to get hit with a lawsuit.

The state of Florida is the seventh launch of this expanded insurance product for Mercury Insurance, after California, Texas, Oklahoma, Illinois, Arizona and Georgia. You can learn more about this unique coverage at Mercury Umbrella Insurance.

“Mercury Insurance offers Floridians additional protection from lawsuits,” said Nick Colby, VP and Chief Sales Officer at Mercury Insurance. “Without this supplemental coverage, your home and car could be at risk.”

A cautionary tale for all is that of a Mercury policyholder who had kept the same limits and coverages since college, even though his personal wealth had increased significantly. The policyholder, who later became a doctor, never thought about umbrella coverage until he hit a moped with his automobile, severely injuring the rider. The rider subsequently engaged a lawyer, and the Mercury insured ended up having to pay out of pocket for damages that were well beyond his auto policy limit of $25,000. 

“This resulted in payments deducted from his salary for a number of years until the settlement was paid off,” Colby said. 

Key features of Mercury’s significantly updated umbrella product include: 

• 3-year Accident and Violation Free Discount: A 5% discount is given to all drivers on the Mercury policy with no losses or accidents during the last three years.

• Uninsured Motorist Coverage: Uninsured motorist coverage up to $1 million in the event of an accident caused by a driver who does not have insurance.

• Increased Liability: Policyholders can increase their liability coverage from $1 million to $2 million, depending upon policyholder coverage needs.

“At Mercury, our umbrella policies provide very tailored extra protection depending on your needs. These policies are perfect for those who want to protect their homes and valuables against unexpected legal judgments and those looking for a quick payday,” stated Colby.

About Mercury Insurance 

Mercury Insurance (NYSE: MCY) is a multiple-line insurance carrier predominantly offering personal auto, homeowners, renters and commercial insurance through a network of independent agents in Arizona, California, Georgia, Illinois, Nevada, New Jersey, New York, Oklahoma, Texas and Virginia, as well as auto insurance in Florida. Mercury writes other lines of insurance in various states, including commercial, business owners and business auto, landlord, home-sharing, ride-hailing and mechanical protection insurance.

Since 1962, Mercury has provided customers with tremendous value for their insurance dollar by pairing ultra-competitive rates with excellent customer service, through more than 4,200 employees and a network of more than 6,340 independent agents in 11 states. Mercury has earned an “A” rating from A.M. Best, as well as “Best Auto Insurance Company” designations from Forbes and Insure.com. For more information visit www.MercuryInsurance.com or follow the company on X, Instagram or Facebook.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bodily-injury-costs-increase-in-florida-according-to-mercury-insurance-302530236.html

SOURCE Mercury Insurance

LOS ANGELES
, Aug. 14, 2025 /PRNewswire/ — Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Sable Offshore Corp. (“Sable” or the “Company”) (NYSE: SOC).

IF YOU SUFFERED A LOSS ON YOUR SABLE INVESTMENTS, CLICK HERE
BEFORE SEPTEMBER 26, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?

The complaint filed alleges that, between May 19, 2025 and June 3, 2025, Defendants failed to disclose to investors that: (1) Defendants represented that Sable Offshore Corp. had restarted oil production off the coast of California when it had not; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 

Glancy Prongay & Murray LLP,  
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sable-offshore-corp-soc-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302529666.html

SOURCE Glancy Prongay & Murray LLP